Aduro Biotech Inc. | Key People and Executives
Stephen T. Isaacs
Chairman, President & Chief Executive Officer
Stephen A. Sherwin
Independent Director
Lok Chung Chan
Independent Director
Francis Patrick McCormick
Independent Director
Stephanie Monaghan O'Brien
Lead Independent Director
William Mariner Greenman
Independent Director
R. Ross Haghighat
Independent Director
Stephen T. Isaacs
Chairman, President & Chief Executive Officer
Jennifer Lew
Chief Financial Officer
Andrea van Elsas
Chief Scientific Officer
Natalie R. Sacks
Chief Medical Officer
Hans van Eenennaam
Executive Vice President-Antibody Research
Liana Wu
Vice President-Commercial
Michele DeVries
Vice President-Regulatory Affairs
Aljanae Reynolds
Media Contact
Nancy Kaplan
VP-Human Resources & Facility Operations
Blaine Templeman
Secretary & Chief Legal Officer
Stephen A. Sherwin
Independent Director
Lok Chung Chan
Independent Director
Francis Patrick McCormick
Independent Director
Stephanie Monaghan O'Brien
Lead Independent Director
William Mariner Greenman
Independent Director
Ross Haghighat
Independent Director
| Address |
740 Heinz Avenue
Berkeley California 94710
United States
|
|
Employees
|
- |
| Website |
http://www.aduro.com |
| Updated |
07/08/2019 |
| Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The firm's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. |
